Liminatus Pharma
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12611 Hiddencreek Way Ste C, Cerritos, C...Phone Number
(213) 273-5453Website
www.liminatuspharma.comRevenue
-Stock Symbol
LIMNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Liminatus Pharma
Liminatus Pharma is a preclinicalstage immunooncology company pioneering the development of a secondgeneration CD47blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with firstgeneration CD47 blockades. Building on more than a decade of CD47blockade immunotherapy development and clinical trial setbacks experienced by numerous bioventures, we engineered an upgraded CD47blockade antibody.Explore more
Popular SearchesLiminatus PharmaLiminatus Pharma LLCLiminatuspharmaSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: LIMNShow moreLiminatus Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Liminatus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Liminatus Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Liminatus Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on Liminatus Pharma recently announced quarterly report
Liminatus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Liminatus Pharma
Product Launch: Get notified when Liminatus Pharma launches new products
Check out if Liminatus Pharma is spiking on competitors!
Funding: Get notified immidiatlly once Liminatus Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Liminatus Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Liminatus Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Liminatus Pharma.
Liminatus Pharma Tech Stack
A closer look at the technologies used by Liminatus Pharma
Liminatus Pharma News & Media
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common StockLiminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price RequirementLiminatus Pharma Amends Definitive Merger Agreement with - GlobeNewswire
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline...Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Liminatus Pharma
Sign Up For FreeTo access detailed company insights
Liminatus Pharma is a preclinicalstage immunooncology company pioneering the development of a secondgeneration CD47blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with firstgeneration CD47 blockades. Building on more than a decade of CD47blockade immunotherapy development and clinical trial setback... Read More
